Vaccine Against Pneumonia: A New Recommendation for Older Adults

Did you know that the Centers for Disease Control and Prevention (CDC) has recently recommended that adults aged 50 and above should get a shot to protect against pneumococcal disease? This decision was made by a scientific panel and then approved by the CDC. This disease is caused by a type of bacteria that can lead to serious illnesses like pneumonia. The aim is to prepare for the upcoming winter season when respiratory issues are common. For many years, this vaccine was only recommended for adults aged 65 and older. But now, people aged 50-64 are also being advised to get the shot. This change was voted on during a meeting in Atlanta, with a majority of 14-1. Doctors usually follow these recommendations, and health insurers often cover the cost of these vaccines. The CDC’s vaccination guidance on pneumococcal disease is complex. It includes shots for children under 5 and adults 65 and older who have never been vaccinated. They also recommend it for people at higher risk, such as those with diabetes or weakened immune systems. Pneumococcal disease can be quite severe. It affects the lungs and other parts of the body. Every year, around 30, 000 people in the U. S. get this disease, and about 30% of these cases are among people aged 50-64. The first pneumococcal vaccine was launched in the U. S. in 1977. Since then, various versions have been created, each targeting different types of the bacteria. Currently, there are four vaccines available. The newest one, Capvaxive by Merck, was approved this year. It costs around $300 per dose and protects against 21 types of bacteria, including some not covered by other vaccines. Merck designed it to protect against the most severe diseases affecting adults aged 50 and older. In June, the CDC advisory panel recommended this vaccine for adults at higher risk. They also discussed lowering the age for routine vaccination. This was pushed until the recent meeting because illness-causing infections peak at a younger age in Black Americans compared to white people. There are still some concerns. A booster shot might be needed in the future, maybe around 15 years from now. Plus, new vaccines in development could lead to another update in recommendations. This makes the whole process quite confusing, according to Dr. Jamie Loehr, who chairs the committee’s pneumococcal working group. He was the only member who voted against the proposal.